The common position of the Czech professional associations on the consensus of the European Atherosclerosis Society and the European Federation of Clinical Chemistry and Laboratory Medicine regarding investigation on blood lipids and interpretation of their levels
Authors:
Vladimír Soška 1,2; Janka Franeková 3; Bedřich Friedecký 4,5; Antonín Jabor 3; Pavel Kraml 6; Hana Rosolová 7; Michal Vrablík 8*
Authors place of work:
International Clinical Research Center, FN U sv. Anny v Brně
; Oddělení klinické biochemie
1; II. interní klinika a Katedra laboratorních metod, LF MU, Brno
2; Pracoviště laboratorních metod IKEM a 3. LF UK, Praha
3; SEKK spol. s r. o., Pardubice
4; Ústav klinické biochemie a diagnostiky, LF UK a FN Hradec Králové
5; Centrum pro výzkum diabetu, metabolizmu a výživy, II. interní klinika 3. LF UK a FN Královské Vinohrady, Praha
6; II. interní klinika LF UK a FN Plzeň
7; III. interní klinika 1. LF a VFN v Praze
8
Published in the journal:
AtheroRev 2017; 2(1): 33-39
Category:
Guidelines
*(za společnou pracovní skupinu)
Tato doporučení jsou dílem společné pracovní skupiny, kterou vytvořily Česká společnost pro aterosklerózu (ČSAT) a Česká společnost klinické biochemie (ČSKB).
Summary
The aim of this opinion is to summarize and to comment the consensus of the European Atherosclerosis Society and European Federation of Clinical Chemistry and Laboratory Medicine, which covers two main areas: 1) whether it is necessary / required to be fasting or non-fasting before blood sampling for lipids measurement, and what are the changes in the concentration of blood lipids during the day; 2) What decision limits (cut off value) of lipids and lipoproteins should be reported from laboratories and what is the recommended procedure for people with extreme / critical blood lipid values. Following parameters are discused: total cholesterol, LDL cholesterol, HDL cholesterol, non-HDL cholesterol, triglycerides, apolipoprotein A1, apolipoprotein B, lipoprotein(a). This opinion should be the object of interest both for professionals in clinical laboratories and for physicians in hospitals and out-patients departments.
Key words:
apolipoproteins, blood collection, cholesterol, laboratory testing, lipoprotein(a), cut off limits, triglycerides
Zdroje
1. Nordestgaard BG, Langsted A, Mora S et al. Fasting is not routinely required for determination of a lipid profile: clinical and laboratory implications including flagging at desirable concentration cut-points-a joint consensus statement from the European Atherosclerosis Society and European Federation of Clinical Chemistry and Laboratory Medicine. Eur Heart J 2016; 37(25): 1944–1958. Dostupné z DOI: <http://dx.doi.org/10.1093/eurheartj/ehw152>.
2. Friedewald WT, Levy RI, Fredrickson DS. Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem 1972; 18(5): 499–502.
3. Mora S, Rifai N, Buring JE et al. Comparison of LDL cholesterol concentrations by Friedewald calculation and direct measurement in relation to cardiovascular events in 27,331 women. Clin Chem 2009; 55(5): 888–894. Dostupné z DOI: <http:dx.doi.org/10.1373/clinchem.2008.117929>.
4. Tanno K, Okamura T, Ohsawa M et al. Comparison of low-density lipoprotein cholesterol concentrations measured by a direct homogeneous assay and by the Friedewald formula in a large community population. Clin Chim Acta 2010; 411: 1774–1780. Dostupné z DOI: <http://dx.doi.org/10.1016/j.cca.2010.07.034>.
5. Piepoli MF, Hoes AW, Agewall S et al. 2016 European Guidelines on cardiovascular disease prevention in clinical practice: The Sixth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of 10 societies and by invited experts): Developed with the special contribution of the European Association for Cardiovascular Prevention & Rehabilitation (EACPR). Eur Heart J 2016; 37(29): 2315–2381. Dostupné z DOI: <http://dx.doi.org/10.1093/eurheartj/ehw106>.
6. Soska V, Vaverkova H, Vrablik M et al. [Opinion of the Czech Atherosclerosis Society‘s committee (CSAT) on the ESC/EAS guidelines related to the diagnostics and treatment of dyslipidemias issued in 2011]. Vnitr Lek 2013; 59(2): 120–126.
7. Catapano AL, Graham I, De Backer G et al. ESC/EAS 2016 guidelines for the management of dyslipidemias. Eur Heart J 2016 Aug 27. pii: ehw272. Dostupné z DOI: <http://dx.doi.org/10.1093/eurheartj/ehw272>.
8. Vaverková H, Soška V, Rosolová H et al. [Czech Atherosclerosis Society Guidelines for the diagnosis and treatment of dyslipidemias in adults]. Vnitr Lek 2007; 53(2): 181–187.
9. Guadagno PA, Summers Bellin EG, Harris WS et al. Validation of a lipoprotein(a) particle concentration assay by quantitative lipoprotein immunofixation electrophoresis. Clin Chim Acta 2015; 439: 219–224. Dostupné z DOI: <http://dx.doi.org/10.1016/j.cca.2014.10.013>.
10. McConnell JP, Guadagno PA, Dayspring TD et al. Lipoprotein(a) mass: a massively misunderstood metric. J Clin Lipidol 2014; 8(6): 550–553. Dostupné z DOI: <http://dx.doi.org/10.1016/j.jacl.2014.08.003>.
11. Raal FJ, Giugliano RP, Sabatine MS et al. Reduction in lipoprotein(a) with PCSK9 monoclonal antibody evolocumab (AMG 145): a pooled analysis of more than 1,300 patients in 4 phase II trials. J Am Coll Cardiol 2014; 63(13): 1278–1288. Dostupné z DOI: <http://dx.doi.org/10.1016/j.jacc.2014.01.006>.
12. Franeková J, Jabor A, Soška V. Vliv standardní zátěže tukem na koncentrace triacylglycerolů a HDL-cholesterolu. FONS 2016; 26(3): 22–24.
13. Emerging Risk Factors C, Di Angelantonio E, Sarwar N et al. Major lipids, apolipoproteins, and risk of vascular disease. JAMA 2009; 302(18): 1993–2000. Dostupné z DOI: <http://dx.doi.org/10.1001/jama.2009.1619>.
14. Driver SL, Martin SS, Gluckman TJ et al. Fasting or Nonfasting Lipid Measurements: It Depends on the Question. J Am Coll Cardiol 2016; 67(10): 1227–1234. Dostupné z DOI: <http://dx.doi.org/10.1016/j.jacc.2015.12.047>.
15. Soška V, Zima T, Friedecký B et al. Společné doporučení České společnosti klinické biochemie ČLS JEP a České společnosti pro aterosklerózu ČLS JEP ke sjednocení hodnotících mezí krevních lipidů a lipoproteinů pro dospělou populaci. Klin Biochem Metab 2010; 18(1): 45–46.
16. Langsted A, Freiberg JJ, Nordestgaard BG. Fasting and nonfasting lipid levels: influence of normal food intake on lipids, lipoproteins, apolipoproteins, and cardiovascular risk prediction. Circulation 2008; 118(20): 2047–2056. Dostupné z DOI: <http://dx.doi.org/10.1161/CIRCULATIONAHA.108.804146>.
Štítky
Angiology Diabetology Internal medicine Cardiology General practitioner for adultsČlánok vyšiel v časopise
Athero Review
2017 Číslo 1
- Advances in the Treatment of Myasthenia Gravis on the Horizon
- Memantine Eases Daily Life for Patients and Caregivers
- Spasmolytic Effect of Metamizole
- Metamizole at a Glance and in Practice – Effective Non-Opioid Analgesic for All Ages
- What Effect Can Be Expected from Limosilactobacillus reuteri in Mucositis and Peri-Implantitis?
Najčítanejšie v tomto čísle
- Adherence to treatment – an important part of reaching therapeutic effects on chronic conditions
- The review of drug interactions and risks of statin therapy
- Adherence to treatment according to the psychologist
- A diabetologist‘s view on the metabolic surgery in the treatment of patients with type 2 diabetes